Boehringer Ingelheim Archives

Boehringer Ingelheim ties up with Indian firm to reach Tier 2 cities

August 25, 20246 min

Boehringer Ingelheim India has entered into a strategic partnership with Vvaan Lifesciences Pvt Ltd to distribute its pet parasiticide portfolio in Tier 2 cities of the country. The collaboration, an initiative under Boehringer Ingelheim India’s animal health accelerated growth plan, marks a significant step in expanding the company’s reach and enhancing customer value in the animal health sector. India’s pet health market is currently worth around €115 million ($129 million, or Rs1,078 crore). According to...

by Sandy Pawpaw

All About Pets Curious Tales

U.S. FDA clears generic from India to treat heart ailment in dogs

April 28, 20245 min

The first generic of veterinary drug pimobendan, used to manage congestive heart failure in dogs due to clinical myxomatous mitral valve disease or dilated cardiomyopathy has been approved by the U.S. Food and Drug Administration. The drug is manufactured by Cronus Pharma Specialities India Pvt Ltd, the Hyderabad-based manufacturing subsidiary of privately held U.S. veterinary drug research company Cronus Pharma based in East Brunswick, New Jersey. The FDA on Thursday approved Pimomedin chewable tablets for...

by Staff Reporter

All About Pets Curious Tales

German pharma company introduces broad-spectrum tablet for parasite control in pet dogs

April 20, 20248 min

Boehringer Ingelheim, a German family-owned research-driven biopharmaceutical company and global leader in animal health, has announced the launch of NexGard SPECTRA® chewable tablets in India following its approval by the Central Drugs Standard Control Organisation. After the launch of NexGard X and L in 2020 and NexGard S and M (afoxolaner) in 2023, this represents an expansion of the NexGard product line for dogs aged at least two months and weighing 2 kg or more....